Kritika Singh

Ms. Kritika Singh

orcid

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2002 in Biochemistry
Verified
Journal Article
Closed access
Bechan SharmaBechan Sharma
Bechan Sharma
NKNeerja Kaushik
Neerja Kaushik
KSKritika Singh
Kritika Singh
SKSuriender Kumar
Suriender Kumar
VPVirendra N. Pandey
Virendra N. Pandey

20 May 2025 in Cancers
Verified
Journal Article
Open access
PDF file
MGMegan Greenberg
Megan Greenberg
TLThomas Lucido
Thomas Lucido
KSKritika Singh
Kritika Singh
JRJoanna Rhodes
Joanna Rhodes
Background: The treatment of chronic lymphocytic leukemia (CLL) has advanced considerably in recent years. Bruton’s tyrosine kinase inhibitors (BTKis) and B-cell lymphoma 2 inhibitors (BCL2is) such as venetoclax have largely supplanted chemoimmunotherapy for both frontline and relapsed CLL. With the introduction of additional innovative agents and regimens, the clinical role of measurable residual disease (MRD) has become complicated. Methods: In this article, we will review the existing literature on MRD and its utility in the management of CLL. We will review the definitions of MRD, review MRD detection methods, and discuss the use of MRD in the current CLL treatment landscape. In doing so, we will clarify the present and conceivable future roles of MRD for the treatment of CLL. Conclusions: MRD is a powerful tool to assess response to CLL therapies, and can be prognostic with certain treatment regimens, such as fixed-duration venetoclax-based treatment. While we do not recommend MRD testing in routine clinical practice, we believe it has an important role in assessing treatment response and will be utilized routinely in the future. Further studies to incorporate MRD into treatment strategies for CLL are ongoing and will help to inform how we utilize it in clinical practice.